Drugs / AP306
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06712654 | Jun 2026 → Feb 2027 expected | end stage renal failure, hyperphosphatemia | R1 Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05764590 | Feb → Aug 2023 | chronic kidney disease, hyperphosphatemia | Alebund Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06712654 ↗ |
| Action | Inhibit | “AP306 is a pan-phosphate transporter inhibitor” NCT06712654 ↗ |
| Route | Oral | “AP306 75 mg by mouth, twice daily (150 mg/day).” NCT06712654 ↗ |